Lung Cancer ► Public Health Genomics Knowledge Base (v1.0)

Public Health Genomics Knowledge Base (v1.0)

What's New

Last Updated: Feb 20, 2016

• HSPB1 polymorphisms might be associated with radiation-induced damage risk in lung cancer patients treated with radiotherapy.
  Li Xiaofeng, et al. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2016 2 (From HuGE Literature Finder)
• Polymorphisms in NF-?B pathway genes & their association with risk of lung cancer in the Chinese population.
  Zhang Jing-Wei, et al. Pakistan journal of medical sciences 0 0 (6) 1411-6 (From HuGE Literature Finder)
• Epidermal growth factor receptor exon 20 p.S768I mutation in non-small cell lung carcinoma: A case report combined with a review of the literature and investigation of clinical significance.
  Improta Giuseppina, et al. Oncology letters 2016 1 (1) 393-398 (From HuGE Literature Finder)
• Sensitive methods for screening of the MEK1 gene mutations in patients with central nervous system metastases of non-small cell lung cancer.
  Nico? M, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2016 2 (From HuGE Literature Finder)
• Clinical and molecular characteristics of NF1 mutant lung cancer.
  Redig Amanda J, et al. Clinical cancer research : an official journal of the American Association for Cancer Research 2016 2 (From HuGE Literature Finder)
• The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.
  Wu Shang-Gin, et al. Oncotarget 2016 2 (From HuGE Literature Finder)
• CLPTM1L polymorphism as a protective factor for lung cancer: a case-control study in southern Chinese population.
  Jin Tianbo, et al. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2016 2 (From HuGE Literature Finder)
• The influence of comorbidity and the Simplified Comorbidity Score (SCS) on overall survival in non-small cell lung cancer - a prospective cohort study.
  Alexander Marliese, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 2 (From HuGE Literature Finder)
• Lung Adenocarcinoma Biomarker Incidence in a Caribbean and African-Caribbean Population.
  Leduc Nicolas, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 2 (From HuGE Literature Finder)
• Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues.
  Sunami Kuniko, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 2 (2) 203-12 (From HuGE Literature Finder)
• Frequencies of EGFR single nucleotide polymorphisms in non-small cell lung cancer patients and healthy individuals in the Republic of Serbia: a preliminary study.
  Obradovi? Jasmina, et al. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 2016 2 (From HuGE Literature Finder)
• Somatic Mosaic Mutations in PPM1D and TP53 in the Blood of Women With Ovarian Carcinoma.
  Swisher Elizabeth M, et al. JAMA oncology 2016 2 (From HuGE Literature Finder)
• Prognostic implications of immunohistochemistry markers for EGFR-TKI therapy in Chinese patients with advanced lung adenocarcinoma harboring EGFR mutations.
  Zhang Ruiguang, et al. OncoTargets and therapy 2016 0 355-66 (From HuGE Literature Finder)
• Complement factor H polymorphism rs1061170 and the effect of cigarette smoking on the risk of lung cancer.
  Ezzeldin Nada, et al. Contemporary oncology (Poznan?, Poland) 2016 0 (6) 441-5 (From HuGE Literature Finder)
• [Genome-wide association study based risk prediction model in predicting lung cancer risk in Chinese].
  Zhu Meng, et al. Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi 2015 10 (10) 1047-52 (From HuGE Literature Finder)
• Study Design and Rationale for a Randomized, Placebo-Controlled, Double-Blind Study to Assess the Efficacy and Safety of Selumetinib in Combination With Docetaxel as Second-Line Treatment in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer (SELECT-1).
  Jänne Pasi A, et al. Clinical lung cancer 2015 12 (From HuGE Literature Finder)
• KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies.
  Pan Wei, et al. Oncotarget 2016 1 (From HuGE Literature Finder)
• Association between two CHRNA3 variants and susceptibility of lung cancer: a meta-analysis.
  Qu Xiao, et al. Scientific reports 2016 0 20149 (From HuGE Literature Finder)
• Efficacy of EGFR tyrosine kinase inhibitors in the adjuvant treatment for operable non-small-cell lung cancer by a meta-analysis.
  Huang Qingyuan, et al. Chest 2015 12 (From HuGE Literature Finder)
• KRAS and NKX2-1 mutations in invasive mucinous adenocarcinoma of the lung.
  Hwang David H, et al. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2016 1 (FromHuGE Literature Finder)